BBOT Q4 and Full Year 2025 Financial Results & Corporate Progress: Detailed Investor Update
BridgeBio Oncology Therapeutics (BBOT) Reports Q4 and Full Year 2025 Financial Results and Corporate Progress
Key Highlights
- BBOT Debuts as Public Company: The company completed its business combination with Helix Acquisition Corp. II, began trading as “BBOT” on Nasdaq Global Market, and launched with three clinical-stage small molecule inhibitors targeting the RAS pathway.
- Pipeline Progress: BBOT reported encouraging preliminary safety and efficacy data across all three programs: BBO-8520, BBO-11818, and BBO-10203. All are designed to target KRAS-driven cancers and PI3Kα pathway, aiming for high-level concurrent suppression of MAPK and PI3Kα pathways.
- Clinical Readouts & Milestones: Pivotal clinical data readouts are expected in the second half of 2026 for all three programs. Internal combinations (KRAS plus PI3Kα) are planned to initiate later in 2026, positioning BBOT for a catalyst-rich period focused on combination viability across KRAS-driven tumor types.
- Financial Position: BBOT ended 2025 with \$425.5 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2028. This supports the advancement of clinical trials and planned combination cohort initiations.
Clinical Program Details – Potential Share Price Catalysts
BBO-8520: KRAS Inhibitor (ON and OFF States)
- Received FDA Fast Track designation for KRAS G12C mutated metastatic NSCLC.
- Phase 1 ONKORAS-101 trial: 65% objective response rate (ORR) and 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment. Notably, a differentiated liver toxicity profile was observed.
- Promising activity in KRAS G12C and STK11/KEAP1 co-mutant patients: All initial patients achieved partial response.
- Combination with pembrolizumab showed efficacy and a distinct safety profile.
- Updated clinical data and internal combination with BBO-10203 planned for H2 2026.
BBO-11818: PanKRAS Inhibitor
- Phase 1 KONQUER-101 trial: First patient dosed in April 2025. Demonstrated the first clinically confirmed partial response (PR) as monotherapy in pancreatic ductal adenocarcinoma (PDAC), with a 56% tumor reduction. No dose-limiting toxicities observed.
- Preclinical data presented at major conferences (AACR-NCI-EORTC) showed potent, selective panKRAS inhibition.
- Further clinical data and internal combination with BBO-10203 anticipated in H2 2026.
BBO-10203: RAS-PI3Kα Breaker
- Novel mechanism: Blocks physical interaction between RAS and PI3Kα, inhibiting PI3Kα-AKT signaling without inducing hyperglycemia or requiring baseline HbA1c/glucose restrictions.
- Preclinical publications (Science, SABCS) and conference presentations demonstrated robust anti-tumor activity in KRAS mutant models, and combination efficacy with BBO-8520 and BBO-11818.
- Phase 1 BREAKER-101 trial: Achieved target engagement, no hyperglycemia, clinical benefit observed in heavily pretreated CRC and HR+ breast cancer patients.
- Updated clinical data and internal combinations expected in H2 2026.
Financial Performance – Key Points for Investors
Q4 2025
- Cash Position: \$425.5 million (expected to fund operations into 2028).
- R&D Expenses: \$38.1 million (up from \$19.5 million in Q4 2024), reflecting higher clinical and manufacturing costs for advancing the pipeline.
- G&A Expenses: \$5.3 million (up from \$2.3 million in Q4 2024) due to standalone operations and de-SPAC transaction.
- Net Loss: \$38.8 million (up from \$19.7 million in Q4 2024).
Full Year 2025
- R&D Expenses: \$121.2 million (up from \$73.1 million in 2024).
- G&A Expenses: \$24.6 million (up from \$7.8 million in 2024).
- Net Loss: \$134.0 million (up from \$74.3 million in 2024).
- Balance Sheet: Total assets of \$448.4 million; total liabilities of \$37.3 million; accumulated deficit of \$356.6 million; total stockholders’ equity of \$411.1 million.
Important Shareholder Updates & Potential Price Sensitivity
- Upcoming Clinical Readouts: Multiple clinical data updates in H2 2026 across all programs could significantly impact share value based on efficacy and safety profiles.
- FDA Fast Track Designation: For BBO-8520 in KRAS G12C NSCLC, enhancing regulatory visibility and potential for expedited development.
- First PanKRAS Response in PDAC: BBO-11818’s demonstration of a monotherapy partial response in pancreatic cancer is a notable industry milestone.
- Cash Runway: BBOT’s strong liquidity position supports ongoing and future clinical trials without near-term financing risk.
- Internal Combination Strategies: Planned combinations (KRAS + PI3Kα inhibition) are a potentially disruptive approach in oncology, with no comparable platform currently in the industry.
Other Corporate Developments
- BBOT completed its business combination with Helix Acquisition Corp. II and began trading under the “BBOT” ticker in August 2025.
Contact Information
Disclaimer
This article contains forward-looking statements based on BBOT’s current expectations and assumptions. Actual results may differ due to risks and uncertainties including changes in market conditions, clinical trial outcomes, regulatory decisions, and other factors discussed in BBOT’s SEC filings. Readers should not rely on these statements as guarantees of future performance. BBOT and its affiliates undertake no obligation to update forward-looking statements except as required by law.
View BridgeBio Oncology Therapeutics, Inc. Historical chart here
